Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon for Sleep Disturbances in ASD
NCT05361707Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tasimelteon in sleep disorder, sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Change in sleep time over the treatment period at 12 weeks. Started Jul 2021; status: recruiting.
02
Drugs
tasimelteon
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT05361707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361707.